Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.45 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5351103 | 0.90 | BACE1 (0.52) | BACE1MAPTMEN1KMT2ANPC1 | |
| SCHEMBL5164310 | 0.90 | BACE1 (0.54) | BACE1MAPTMEN1KMT2ANPC1 | |
| SCHEMBL7814604 | 0.89 | BACE1 (0.53) | BACE1MAPTMEN1KMT2ANPC1 | |
| SCHEMBL28855630 | 0.84 | MEN1 (0.51) | BACE1MAPTMEN1KMT2ANPC1 | |
| SCHEMBL29901056 | 0.84 | MEN1 (0.51) | BACE1MAPTMEN1KMT2ANPC1 | |
| SCHEMBL14191577 | 0.84 | BACE1 (0.53) | BACE1MAPTMEN1KMT2ANPC1 | |
| SCHEMBL29901207 | 0.84 | BACE1 (0.53) | BACE1MAPTMEN1KMT2ANPC1 | |
| SCHEMBL6598985 | 0.82 | TSHR (0.49) | BACE1MAPTMEN1KMT2ANPC1 | |
| SCHEMBL4929920 | 0.82 | BACE1 (0.54) | BACE1PARP10MAPTMEN1KMT2A | |
| SCHEMBL14355554 | 0.81 | BACE1 (0.50) | BACE1MAPTMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070067922-A1 | 4-Aminophenol derivatives and colorants comprising these compounds | PROCTER & GAMBLE COMPANY, THE | 2007-03-29 | — | — | US | disclosed |
| EP-1762218-A1 | 4-aminophenol derivatives and colorants comprising these compounds | Wella Aktiengesellschaft (DE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2007026313-A2 | 4-AMINOPHENOL DERIVATIVES AND COLORANTS COMPRISING THESE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070067922-A1 | 4-Aminophenol derivatives and colorants comprising these compounds | KRT18, S100A4, CKAP4 | BACE1 4847/4885PARP10 3362/4885MAPT 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.